Nuvation Bio

nuvation bio (nyse: nuvb) is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. nuvation bio’s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. nuvation bio was founded in 2018 by biopharma industry veteran david hung, m.d., who previously founded medivation, inc., which brought to patients one of the world’s leading prostate cancer medicines. nuvation bio has offices in new york and san francisco.